Close menu

December 8th, 2022 | 09:05 CET

Where the money is made: BioNTech, Novavax, Cardiol Therapeutics

  • Biotechnology
  • Covid19
  • CBD
Photo credits:

While the first federal states in Germany are lifting the mask requirement on public transport, suppliers of vaccines and medicines are far from going back to normal. Even corona vaccines are in high demand. While there is a shortage of antipyretics and medication in this country, especially for children, innovative companies are already addressing the next challenges. We explain where investors can make money.

time to read: 2 minutes | Author: Nico Popp

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech: Good starting position

    Recently, the BioNTech share price experienced a minor shock: In the legal dispute with Moderna, the Mainz-based company filed a counterclaim with its partner Pfizer. The share price then dipped briefly - investors do not like legal disputes. However, the decline did not cloud the overall chart picture. BioNTech's share price is still driven by the Corona vaccine. Above all, the hope of orders from China makes investors' hearts beat faster. But BioNTech is also doing well in other regions of the world: most recently, Bahrain also opted for the adapted vaccine. Current studies show that the adapted vaccines are worthwhile. According to these, the antibody level in people over 55 years of age increases ninefold with the BQ1.1 variant.

    Novavax: The air is out

    Since BioNTech is flexibly positioned thanks to its mRNA technology and can also focus on other diseases, such as cancer, the stock remains promising. Although the stock is moving sideways between EUR 127 and EUR 176 in 2022, this could be a good starting point for rising prices towards old highs in the long term. The Novavax share also looks attractive from a chart perspective at first glance. However, a closer look reveals differences. First, Novavax does not rely on modern mRNA technology. In the race with the top dogs BioNTech and Moderna, Novavax cannot keep up with its delayed market entry. Only the vaccine against the RS virus, which is currently circulating strongly among children, gave hope for a while - but it ultimately failed in Phase 3 of the clinical trials. While the BioNTech share could regain its strength in the long term, Novavax is likely to have run out of steam for the time being.

    Cardiol Therapeutics: Enormous comeback potential

    At first glance, the air is also out of the Cardiol Therapeutics share. Within the past 14 months, the stock has plummeted from around USD 4.60 to the current level of USD 0.52. What happened? The innovative biotech company, which focuses on inflammatory diseases of the heart, raised fresh capital in 2021 to advance its clinical trials. Fortunately, it could do so at much higher prices than today. The general market environment and share dilution subsequently led to a sell-off at Cardiol. Finally, a few weeks ago, a research program to investigate the effect of the active ingredient CardiolRx in COVID patients was cancelled. Although the drug is still expected to be effective when COVID patients develop concomitant diseases such as myocarditis, the Company simply could not find enough patients to complete the study. Cardiol is now focusing on myocarditis, pericarditis and acute heart failure. Around the first two conditions, Cardiol Therapeutics is in Phase 2 of the development pipeline.

    When pharmacologists are asked about the prospects for Cardiol Therapeutics, they praise the study design in particular. It is capable of producing clear results and also relies on modern methods. While the Novavax share has little chance of surprising positively with its current pipeline, the situation with Cardiol Therapeutics is different. The Company has the necessary capital and has launched promising studies. The active ingredient CBD is considered extremely low in side effects and has already demonstrated anti-inflammatory effects in many studies. Given the sell-off of the Cardiol Therapeutics share, investors should note the value - a dynamic catch-up movement cannot be ruled out here. It is worth keeping an eye on the newsflow! As soon as something happens here, the Nasdaq-listed stock should quickly be back in the focus of investors.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST

    Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

    • Biotechnology
    • Pharma
    • renewableenergies

    The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.


    Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST

    Bayer, Defence Therapeutics, Novavax - Major events

    • Biotechnology
    • Pharma

    The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.


    Commented by André Will-Laudien on May 9th, 2024 | 07:00 CEST

    Biotech and pharma stocks finally follow suit! Novo Nordisk, Bayer, BioNTech, Vidac Pharma and Evotec on the buy list

    • Biotechnology
    • Pharma

    Things looked very different at the beginning of the year. After a brilliant rally in the Nasdaq Biotech Index at the end of last year, investors thought the upswing could continue in 2024. So far, this hope has not been confirmed. The main focus for the industry is the refinancing conditions. These have gradually deteriorated, as stubborn inflation is keeping central bank interest rates high. And judging by the wording of central bankers, the next interest rate cut does not seem to be penciled in yet. However, if it happens in the summer, things will likely move quickly for the life sciences sector. Then a quick sector rotation is the order of the day! Here is our buy list for the upcoming event.